A
Adilia Hormigo
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 54
Citations - 3202
Adilia Hormigo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Glioma & Bevacizumab. The author has an hindex of 21, co-authored 46 publications receiving 2831 citations. Previous affiliations of Adilia Hormigo include University of Rochester Medical Center & Cornell University.
Papers
More filters
Journal ArticleDOI
CD133 expression is not restricted to stem cells, and both CD133 + and CD133 – metastatic colon cancer cells initiate tumors
Sergey V. Shmelkov,Jason M. Butler,Andrea T. Hooper,Adilia Hormigo,Jared S Kushner,Till Milde,Ryan St Clair,Muhamed Baljevic,Ian A. White,David K. Jin,Amy Chadburn,Andrew J. Murphy,David M. Valenzuela,Nicholas W. Gale,Gavin Thurston,George D. Yancopoulos,Michael I. D’Angelica,Nancy E. Kemeny,David Lyden,Shahin Rafii +19 more
TL;DR: The data suggest that CD133 expression is not restricted to intestinal stem or cancer-initiating cells, and during the metastatic transition, CD133+ tumor cells might give rise to the more aggressive CD133(- )subset, which is also capable of tumor initiation in NOD/SCID mice.
Journal ArticleDOI
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice
Sergey V. Shmelkov,Adilia Hormigo,Adilia Hormigo,Adilia Hormigo,Deqiang Jing,Catia C. Proenca,Catia C. Proenca,Kevin G. Bath,Till Milde,Evgeny Shmelkov,Jared S Kushner,Muhamed Baljevic,Iva Dincheva,Andrew J. Murphy,David M. Valenzuela,Nicholas W. Gale,George D. Yancopoulos,Ipe Ninan,Francis S. Lee,Shahin Rafii +19 more
TL;DR: It is demonstrated that loss of a neuron-specific transmembrane protein, SLIT and NTRK-like protein-5 (Slitrk5), leads to OCD- like behaviors in mice, which manifests as excessive self-grooming and increased anxiety-like behaviors, and is alleviated by the selective serotonin reuptake inhibitor fluoxetine.
Journal ArticleDOI
Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma
TL;DR: Long-term follow-up of the initial cohort confirms the observation of excellent overall survival, particularly for those patients younger than age 60 at diagnosis, and it appears to be reasonable to defer whole brain radiotherapy in an effort to minimize treatment-related neurotoxicity.
Journal ArticleDOI
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Adilia Hormigo,Bin Gu,Sasan Karimi,Elyn Riedel,Katherine S. Panageas,Mark A. Edgar,Meena K. Tanwar,Jasti S. Rao,Martin Fleisher,Lisa M. DeAngelis,Eric C. Holland +10 more
TL;DR: YKL-40 can be used as predictor of survival in patients with high-grade glioma and MMP-9 can be monitored in patients' serum and help confirm the absence of active disease in GBM and YKL -40 in anaplasticglioma patients.
Journal ArticleDOI
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer Clarke,Fabio M. Iwamoto,Joohee Sul,Katherine S. Panageas,Andrew B. Lassman,Lisa M. DeAngelis,Adilia Hormigo,Craig Nolan,Igor T. Gavrilovic,Sasan Karimi,Lauren E. Abrey +10 more
TL;DR: Both dose-dense and metronomic temozolomide regimens were well tolerated with modest toxicity and the dose- dense regimen appears promising, with 1-year survival of 80%.